NCT00334893View on ClinicalTrials.gov

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Fallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Interventions
DRUG

eribulin mesylate

Given IV

Trial Locations (2)

10065

Memorial Sloan-Kettering Cancer Center, New York

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00334893 - Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter